

RealRate

PHARMACEUTICAL 2018

## PROCYON CORP Rank 29 of 342







RealRate

PHARMACEUTICAL 2018

PROCYON CORP Rank 29 of 342

The relative strengths and weaknesses of PROCYON CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of PROCYON CORP compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 202% points. The greatest weakness of PROCYON CORP is the variable Other Expenses, reducing the Economic Capital Ratio by 145% points.

The company's Economic Capital Ratio, given in the ranking table, is 249%, being 203% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	1,592
Cost of Goods Sold	0
Intangible Assets	17
Liabilities, Current	440
Liabilities, Non-Current	0
Other Assets	607
Other Compr. Net Income	0
Other Expenses	2,846
Other Liabilities	2.1
Other Net Income	-0.98
Other Revenues	4,012
Property and Equipment	514
Research and Development	0
Selling, General and Administrative Expense	1,153

Output Variable	Value in 1000 USD
Assets	2,730
Liabilities	442
Expenses	3,999
Revenues	4,012
Stockholders Equity	2,288
Net Income	12
Comprehensive Net Income	12
Economic Capital Ratio	249%

